Krystal Biotech Reports Today as Shorts Retreat

KRYS enters its Q3 print with short sellers materially less committed than they were a month ago. Short interest has dropped 18% over the past 30 days to 9.9% of the free float, a decline that ORTEX measures as 3.2 standard deviations below the company's typical weekly move over the past year. That is a meaningful retreat, not noise. Borrow costs remain near the floor at 0.45%, and with availability at 422%, there are more than four shares available to borrow for every one currently lent, a loose lending market that gives shorts every opportunity to add if they wanted to. The fact they have not is the story. Options positioning reflects neither panic nor euphoria: the put/call ratio of 1.09 sits just below its 20-day average of 1.17, slightly less defensive than usual rather than crowded in either direction.

The analyst community has been persistently constructive. Goldman Sachs reinstated coverage in late September with a Buy and a $441 target. Bank of America has raised its target twice this year, most recently to $400. The consensus target of $395 implies roughly 19% upside from Friday's close of $332. The bear case is specific and worth taking seriously: VYJUVEK's US revenues appear to have plateaued in the $88 million to $99 million range since Q4 2024, the company's own $500 million full-year sales guidance implies limited sequential growth, and the 2cc-bottle coverage constraint means each application treats only a fraction of a patient's affected skin. On the other side, a 94% gross margin, $1 billion in cash, and a pipeline with four HSV-1 platform programmes at various stages give the bulls a credible long-term compounding argument. At 38x trailing earnings and an EV/EBITDA of roughly 30x, both multiples slightly higher than a month ago, the stock prices in a fair amount of that optimism already.

One data point complicates the commercial momentum narrative. ORTEX Alt Data, drawing on Centers for Medicare and Medicaid Services records, shows Medicaid prescriptions for KRYS's drug down 36% against Q1 last year, with Medicaid dollars reimbursed down 11% over the same period. These figures cover Q1 2026 and are not a forecast of today's print, but a 36% year-on-year decline in Medicaid prescription volume is a concrete softness in one payer channel that the bull case around VYJUVEK's broadening reach will need to address.

KRYS rose 6.7% over the past week, roughly in line with the 5.5% median for its closest peers. BEAM and TGTX both climbed more than 13% over the same period, while DNLI and VYGR lagged. Institutional holders added exposure in Q3: BlackRock grew its stake by nearly 950,000 shares to 11.6% of the company, State Street added close to 200,000 shares, and T. Rowe Price added more than 200,000. The CEO, Krish Krishnan, sold approximately $6.5 million of stock in early September, all under a pre-arranged 10b5-1 plan, which limits the signal value of the transactions. Wikipedia attention for KRYS spiked sharply in mid-October, with a z-score of 6.5 against the stock's own 90-day history, suggesting a surge in retail interest in the days before today's report.

Today's report tests whether VYJUVEK's commercial trajectory justifies a 30x EBITDA multiple when the domestic revenue line appears to have stalled, and whether the pipeline's early-stage promise can maintain institutional confidence through a period of slower near-term growth.